Royalty Pharma plc - Ordinary Shares - Class A

-0.17 (-0.42%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)17.14B
Current PE11.03
Forward PE 14.09
2yr Forward PE 12.67
See more stats
Estimates Current Quarter
Revenue$545.56 Million
Adjusted EPS$0.78
See more estimates
10-Day MA$40.20
50-Day MA$39.91
200-Day MA$39.79
See more pivots

Royalty Pharma plc - Ordinary Shares - Class A Stock, NASDAQ:RPRX

110 East 59th Street, 33rd floor, New York, New York 10022
United States of America
Phone: +1.212.883.0200
Number of Employees: 51


Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&Jâ??s Imbruvica, Astellas and Pfizerâ??s Xtandi, Biogenâ??s Tysabri, Gileadâ??s HIV franchise, Merckâ??s Januvia, Novartisâ?? Promacta, Vertexâ??s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.